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SUMMARY

Lindsey Thompson is
a ketogenic dietitian at
Children’s Mercy’s
Comprehensive
Epilepsy Center.

Drug-resistant epilepsy poses a challenge in neonatal patients, especially those in the
neonatal intensive care unit (NICU), who have various secondary comorbidities. We
present results of four children with a history of drug-resistant epilepsy for whom a
ketogenic diet was initiated and used in the NICU. A nonfasting induction into ketosis
over 1–2 weeks was utilized, with gradual increases in the ketogenic ratio every
2–3 days. Data were collected retrospectively from a database, which included medical history, daily progress notes, relevant laboratory data, and imaging and diagnostic
information. The ketogenic diet was well tolerated in all cases. The most common side
effects observed were constipation, hypoglycemia, and weight loss. Serum b-hydroxybutyrate levels demonstrated improved reliability as a marker of ketosis when compared to urine ketones in this population. Perceived benefits to the infants included
improved seizure control, increased alertness, and decreased need for invasive respiratory support. These cases demonstrate that the use of the ketogenic diet for treatment of neonatal encephalopathy and refractory epilepsy can be undertaken safely in
the NICU and is well tolerated by carefully screened neonates and infants.
KEY WORDS: Diet therapies, Neonatal intensive care unit, Refractory epilepsy,
Nonpharmacologic.

The ketogenic diet is a high-fat, low-carbohydrate diet
that is an effective treatment for reducing seizures in infants
and children with drug-resistant epilepsy.1,2 A 2012
Cochrane Review reported that the benefits of a ketogenic
diet are comparable to those of modern antiepileptic drugs
(AEDs).2 The ketogenic diet has been studied previously in
infants with refractory epilepsy and has been demonstrated
to be safe and effective.3–5 Klepper et al.3 described the use
of the ketogenic diet in four young infants, and Nordli
et al.,4 reported that the diet had equal efficacy in 32 infants,
including medication weaning, when compared to previous
studies of older children. Kayyali et al.,5 described successful and efficacious use of the diet in 15 infants with refractory epileptic spasms. However, these studies have not

described the use of ketogenic diet in critically ill hospitalized infants. Drug-resistant epilepsy poses a challenge in
infant patients, especially those in the neonatal intensive
care unit (NICU) who have various secondary comorbidities. There is a single published case report that includes one
patient, 9 weeks of age, for whom the ketogenic diet was
successfully used to treat refractory status epilepticus in the
NICU.6 Nonetheless, no other data have been published on
the safety and tolerability of the ketogenic diet in infants
being treated for epileptic encephalopathy and refractory
seizures in the NICU. Thus, we present data on four infants
with a history of drug-resistant epilepsy for whom the ketogenic diet was initiated and used in the NICU.

Methods
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The Children’s Mercy Hospital Institutional Review
Board approved this study. Data were collected retrospectively from a database, which included medical history,
daily progress notes, diet information, relevant laboratory
data, imaging findings, and electroencephalography (EEG)
monitoring. Frequency of clinical seizures, complications,
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Ketogenic diet initiation was well tolerated in all infants
studied. Ketosis was achieved in all cases as evidenced by
serum ketone level (Fig. 1). Urine ketones were variable
and did not correlate directly with serum levels of ketosis
(Fig. 1). In case 1, the infant required continuous nasogastric feedings due to preexisting hypoglycemia that persisted,
although did not worsen, with ketogenic diet induction.

Medical history

Results

Table 1. Patient demographics

and perceived benefits noted with ketogenic diet initiation
were collected via caregiver and medical staff report.
Patient demographics are presented in Table 1. All patients
failed to respond to at least three AEDs prior to ketogenic
diet initiation. Failure was defined as continued seizures
despite appropriate doses of AEDs. Metabolic screening,
including serum amino acids, urine organic acids, and acylcarnitine panel, was performed for all patients prior to diet
initiation, as well as evaluation for contraindications to the
ketogenic diet, as outlined previously by Kossoff et al.7 All
patients had EEG studies performed before and after ketogenic diet initiation, but there was no standard time for completion of EEG.
A nonfasting induction into ketosis over 1–2 weeks
was utilized, with gradual increases in the ketogenic ratio
every 2–3 days, starting with a ketogenic ratio of 1:1.
Diet ratio was titrated until a blood ketone level
>3,000 lmol/L was achieved. Diet ratio was adjusted further in response to perceived benefit to seizure control,
infant alertness, or decreased need for respiratory support.
The highest ratio utilized was 4:1. The following lab monitoring was performed during diet initiation: basic metabolic panels daily, urine dipstick for ketones with each
void, and serum b-hydroxybutyrate every other day.
Blood glucose was monitored with fingerstick four times
daily or as needed based on clinical course. Frequency of
laboratory blood draws were minimized to preserve infant
blood volume. Ketogenic formulas (KetoCal 4:1 LQ,
Nutricia North America, and Ross Carbohydrate Free,
Abbott Nutrition) and modular products (MCT Oil, Nestle, and Liquid Protein Fortifier, Abbott Nutrition) were
used to initiate the diet. In case 4, the patient’s ketogenic
formula was mixed with the mother’s breast milk to the
prescribed ketogenic ratio. All patients required additional
vitamin and mineral supplementation to meet 100% of
micronutrient requirements per Institute of Medicine recommendations.8
All four patients were discharged home from the NICU
on the ketogenic diet and were followed in the outpatient
clinic every 3 months. Clinic visits consisted of anthropometric assessment, clinical evaluation, and discussion of
diet efficacy with caregivers. Laboratory data collected at
follow-up visits included basic metabolic panel, liver function tests, serum b-hydroxybutyrate level, lipid panel, and
serum micronutrients.

Outcomes
to date
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Figure 1.
Serum betahydroxybutyrate levels at each ketogenic diet ratio for cases 1–4 correlated with urine ketone measurements.
Epilepsia ILAE

None of the infants in this series required intravenous fluids
or intravenous nutrition support during diet initiation.
A reduction in clinical seizures was reported subjectively
by caregivers and/or medical staff in three of four cases
(cases 1, 2, and 4). However, only the EEG in case 4 demonstrated improved organization and decreased seizures after
diet initiation. This patient became seizure-free within
2 weeks of starting the ketogenic diet. In case 3, caregivers
did not report a reduction in seizure activity, and this observation was supported by continued seizures on EEG. None
of the EEG findings demonstrated worsening of epilepsy;
however, evolution of epileptic encephalopathy was
observed in three of the four cases (cases 1–3).
Improved response to environmental stimuli was reported
in all four cases by caregivers. Case 1 and case 2, who were
intubated at baseline, were successfully extubated and
weaned to either nasal cannula or room air after ketogenic
diet initiation.
The most common side effects observed were constipation, hypoglycemia, and weight loss. Constipation was
noted in cases 1 and 2. Constipation was successfully treated
with glycerin suppositories and addition of MCT oil to the
patients’ formula. Case 1 experienced low blood glucose
(defined as <40 mg/dl). Ten milliliters of juice was given
acutely and progress of diet initiation was slowed, which
resulted in improved blood glucose levels. Weight loss was
a problem for case 1 initially, but resolved with calorie
adjustments and the addition of MCT oil (5% of fat calories)
to formula.
All four infants remain on ketogenic diet for management
of epilepsy (Table 1). All infants were able to have at least
one medication weaned after starting ketogenic diet, with
two of the four infants having more than one medication
weaned. No cases exhibited elevated cholesterol levels after
ketogenic diet initiation.
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Discussion
These cases demonstrate that initiation of the ketogenic
diet for treatment of refractory epilepsy can be undertaken
safely in the NICU and is well tolerated in carefully
screened infants. Although the efficacy of the ketogenic diet
for seizure control cannot be determined in this small population, the caregivers and medical staff reported reductions
in numbers of clinical seizures, an observation supported by
EEG findings in one patient. Unanticipated improvements
in alertness and respiratory effort suggest additional benefit
to support the use of this treatment option in infants in the
NICU.
Serum b-hydroxybutyrate levels demonstrated improved
reliability as a marker of ketosis when compared to urine
ketones in this population, which has been noted previously.3 Metabolic complications, including hypoglycemia,
were consistent with previously reported side effects of the
ketogenic diet in infants3–6,9 and were easily managed with
standard interventions. Acute weight loss, which was noted
in case 1, was also reported previously in an infant started
on the ketogenic diet by Goyens et al.9 In both instances,
weight loss was reversed successfully with the addition of
MCT oil to the infant’s formula. Hyperlipidemia is commonly reported with ketogenic diet use,10 including in
infants4; however, this was not observed in any cases at follow-up clinic visits.
Education of staff and caregivers is vital for successful
use of this treatment option in the NICU. Initial obstacles to
ketogenic diet initiation in the NICU included the following: staff inexperience with the metabolic effects and monitoring required for ketogenic diet initiation, concern by
NICU physicians that use of the ketogenic diet would
prevent infants from receiving appropriate nutrition and
limit weight gain, incorrect ordering of formula, and
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inappropriate administration of glucose to treat hypoglycemia. Written, verbal, and online education was provided for staff by the ketogenic diet team, which included
physicians, nurse practitioners, and dieticians. The material
provided has since been formalized into ongoing education
offerings. Development of new order sets in the electronic
medical record, specific to ketogenic diet initiation, allowed
for accurate and streamlined patient management. Identification of dextrose in the electronic medical record as a cause
of adverse reaction for all patients on the ketogenic diet
improved institutional awareness to possible medication/infusion formulation errors.

Conclusion
In these cases, the ketogenic diet was safe and well tolerated as an adjunct therapy for intractable epilepsy in the
NICU. Perceived benefits for the infants included improved
seizure control, increased alertness and decreased need for
invasive respiratory support. Careful attention to education
of all caregivers and medical staff must be assumed prior to
and during use of the ketogenic diet in the NICU to maximize benefit and limit risk to patients. Further study with a
larger patient sample size is needed to determine if perceived benefits seen in this case series are statistically supported.

We confirm that we have read the Journal’s position on issues involved in
ethical publication and affirm that this report is consistent with those guidelines.
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